Home›Trial›NCT03837899
🔬NCT03837899Phase 1Phase 2ACTIVE NOT RECRUITING

Durvalumab and Tremelimumab for Pediatric Malignancies

Study Summary

The purpose of the study is to determine the recommended dose of durvalumab and tremelimumab (immunotherapy drugs) in pediatric patients with advanced solid and hematological cancers and expand in a second phase to test the efficacy of these drugs once this dose is determined.

Conditions
Pediatric CancerSolid Tumor PediatricHematological Malignancies
Interventions / Drugs
Durvalumab / Tremelimumab Combination Therapy
View on ClinicalTrials.gov ↗
Sponsor
AZN
AstraZeneca
Oncology/Respiratory
F15/100
Study Details
Enrollment50 participants
Primary Completion—
Lead SponsorAstraZeneca
Data Retrieved2026-04-11 02:55:19.910320+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.